Basilea Pharmaceutica AG engages in the development and commercialization of pharmaceutical products. The company is headquartered in Allschwil, Basel-Landschaft and currently employs 164 full-time employees. The company went IPO on 2004-03-25. The firm operates in one segment, which is the discovery, development, and commercialization of pharmaceutical products to meet the needs of patients with severe bacterial and fungal infections. The company launched two hospital brands, Cresemba, which is an intravenous and oral drug for the treatment of invasive fungal infections, and Zevtera, which is an intravenous antibiotic for the treatment of severe bacterial infections, especially pneumonia. Additionally, the Company has several preclinical anti-infective assets in their portfolio. Company's products are present in United States, Canada, Europe, Asia, and Africa.
Follow-Up Questions
What is the price performance of BPMUF stock?
The current price of BPMUF is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Basilea Pharmaceutica AG Allschwil?
Basilea Pharmaceutica AG Allschwil belongs to Biotechnology industry and the sector is Health Care
What is Basilea Pharmaceutica AG Allschwil market cap?
Basilea Pharmaceutica AG Allschwil's current market cap is $0
Is Basilea Pharmaceutica AG Allschwil a buy, sell, or hold?
According to wall street analysts, 9 analysts have made analyst ratings for Basilea Pharmaceutica AG Allschwil, including 4 strong buy, 5 buy, 2 hold, 0 sell, and 4 strong sell
